Current Edition

Using Machine Learning to Identify At-Risk Sites in Acute Schizophrenia Clinical Trials

Data quality concerns are frequent in schizophrenia clinical trials, causing many to suffer from drug placebo separation. Machine learning offers the opportunity to proactively identify raters and sites at risk of developing data quality concerns for early intervention. Xingmei Wang, Emanuel Pintilii, Andrei Iacob and Dr. Alan Kott at Signant Health explore more about using machine learning to identify at-risk sites in acute schizophrenia clinical trials.